0001562180-23-001079.txt : 20230207
0001562180-23-001079.hdr.sgml : 20230207
20230207161045
ACCESSION NUMBER: 0001562180-23-001079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230203
FILED AS OF DATE: 20230207
DATE AS OF CHANGE: 20230207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Benecchi Christopher
CENTRAL INDEX KEY: 0001881403
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 23595175
MAIL ADDRESS:
STREET 1: C/O SAGE THERAPEUTICS, INC.
STREET 2: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-02-03
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001881403
Benecchi Christopher
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
Chief Business Officer
Common Stock
2023-02-03
4
A
false
6750.00
0.00
A
7379.00
D
Common Stock
2023-02-03
4
F
false
2119.00
44.16
D
5260.00
D
On October 1, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 22,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 6,750 shares.
Reflects beneficial ownership balance which includes 414 shares purchased on June 30, 2022 and 215 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.
/s/ Anne Marie Cook, as Attorney-in-Fact for Christopher Benecchi
2023-02-07
EX-24
2
cbenecchipoa.txt
POA
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer)
and Jennifer Fitzpatrick (VP, Corporate Counsel), for as long as they
remain employees of Sage Therapeutics, Inc., and Stuart Falber of
WilmerHale, each acting singly, or their successors in role, to take
the following actions, acting as my agent and attorney-in-fact, with
full power of substitution:
(1) to prepare and sign on my behalf any Form 4 or Form 5
pursuant to Section 16 of the Securities Exchange Act of 1934, as
amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am a director or
executive officer of Sage Therapeutics, Inc., and shall not be
affected by my subsequent disability or incompetence. I may revoke
this Power of Attorney by written notice delivered, in person or by
nationally recognized courier, to the attention of the SVP, General
Counsel of Sage Therapeutics, Inc.
/s/ Christopher Benecchi
Name: Christopher Benecchi
Date: September 13, 2021
P (617) 299-8380 . F (617) 299-8379 . 215 First Street, Cambridge, MA 02142